News Article
According to an April 22 press release from Johnson & Johnson, the European Commission (EC) has approved CARVYKTI (ciltacabtagene autoleucel; cilta cel) as the “first BCMA-targeted treatment for relapsed and refractory multiple myeloma (RRMM) patients who have received at least one…
Videos
Patient Relapse During Clinical Trial
In today's Ask Dr. Durie video, myeloma expert Dr. Brian G.M. Durie discusses what should be done if a patient relapses while in a clinical trial.
Biochemical relapse means that the level of myeloma protein has increased by at least 25% and…
Videos
CRAB and pre-CRAB Criteria in Myeloma Diagnosis
In this week's Ask Dr. Durie episode, myeloma expert Dr. Brian G.M. Durie defines CRAB and pre-CRAB criteria in myeloma diagnosis and how they affect treatment decision-making.
CRAB criteria are vital for diagnosing myeloma: 'C'…
News Article
International Myeloma Foundation Celebrates ODAC Meeting Outcome on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval of Myeloma Drugs in Clinical Trials: A Huge Win for the Global Myeloma Community.
This conclusion is the result of…
Page
People of Color Face Disparities in Access to Clinical Trials, New Drugs, and New Therapies Data from the 2015-2019 FDA Drug Trials Snapshot showed that White people comprise over 70 percent of clinical trial participants even though almost 40 percent of the U.S. population is comprised of…
Videos
The Value of MRD Testing for Myeloma
In today's Ask Dr. Durie video, myeloma expert Dr. Brian G.M. Durie discusses the value of minimal residual disease testing for myeloma patients.
MRD testing detects residual myeloma after treatment, offering valuable insights into disease status…
News Article
STUDIO CITY, April 11, 2024—The International Myeloma Foundation (IMF) and Black Swan Research Initiative® (BSRI) announced the recently published cohort study by the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) team on the “Development of a Multivariable Model…
News Article
In an April 5 press release from Johnson & Johnson, it was announced that the FDA "approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a…
News Article
According to this press release from Bristol Myers Squibb and 2seventy bio, "On April 4, 2024, the U.S. Food and Drug Administration (FDA) approved Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior…
Videos
Gain valuable insights about nutrition in this Q&A replay from myeloma specialist Dr. Urvi A. Shah, who is spearheading research aimed at developing dietary guidelines for hematological malignancies such as multiple myeloma. Hear Dr. Shah's expert opinion on plant-based foods and supplements…
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth!
News Article
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth!
2024 Myeloma Action Month Global Campaign Brings Wave of Myeloma Awareness to 36 Countries Worldwide
STUDIO CITY, CA, April 4, 2024 — At the conclusion of this year’…
Videos
ODAC Hearing on Early Use of CAR T-cell Therapy
Myeloma expert Dr. Brian G.M. Durie discusses the Oncologic Drugs Advisory Committee (ODAC) hearing's impact on the use of early CAR T-cell treatment in myeloma.
Concerns emerged regarding the complexities of bridging therapy,…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the March 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
News Article
IMF Grassroots Patient Advocacy
YOU can help drive meaningful change for patients with myeloma
By Emma Hatcher, IMF Global Vice President, Patient Engagement & Advocacy
Every day, critical healthcare issues are discussed on Capitol Hill, in the White…
Videos
International Myeloma Foundation (IMF) Vice President of Support Groups Robin Tuohy will moderate presentations by Joanna Fawzy Doran, Esq., Triage Cancer CEO and Cancer Rights Attorney. …
Videos
Replay the enlightening Myeloma Action Month live event with IMF NLB Member Beth Faiman as she shares personal anecdotes and addresses viewers' pressing myeloma questions. Beth's expertise shines through as she delves into discussions about treatment options, symptom management, and the latest…
Videos
Replay the Myeloma Action Month Q&A session live from the IMF's Patient and Family Seminar with Dr. Joseph Mikhael and Dr. Gurbakhash Kaur. In this engaging recording, Dr. Mikhael and Dr. Kaur shared valuable insights into the latest developments in multiple myeloma treatment and research. From…
News Article
In this March 20, 2024 press release from Bristol Myers Squibb, it was announced that "the European Commission (EC) has granted approval to Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two…
Videos
Considerations for Multiple Myeloma Immune Therapy
Myeloma expert Dr. Brian G.M. Durie discusses how immune therapy targets, side effects, and monitoring should be considered in multiple myeloma treatment.
Dr. Durie discusses considerations for immune therapy for the treatment of…
News Article
Myeloma Survivor, Advocate, and… Disruptor!
Kent Oliver supports the transformative potential of the IMF’s innovative Myeloma Knowledge Platform
By Sylvia Dsouza, IMF Vice President, Development
Oliver, a longstanding donor, resilient myeloma survivor,…
News Article
According to this March 15, 2024, press release from Bristol Myers Squibb and 2seventy bio, "the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients…
News Article
In a March 15, 2024 press release from Johnson & Johnson, it was reported that "the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommends CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed or refractory…
Videos
IMF Patient and Family Seminars gather highly esteemed global myeloma researchers and healthcare professionals under one roof to share the latest developments in the field of myeloma and to answer your questions about the disease firsthand.
News Article
STUDIO CITY, CA, March 14, 2024 — The International Myeloma Foundation (IMF) is thrilled to welcome lifelong philanthropist and 17-year myeloma survivor John O’Dwyer to the IMF Board.
Prior to his recent election, John served on the IMF Board from 2010-2016 and made many…
Videos
Insights from the iStopMM Project: Preventing Myeloma Progression
Myeloma expert Dr. Brian G.M. Durie discusses how the iStopMM project in Iceland is studying myeloma at the earliest stage, specifically at the point of MGUS, to potentially prevent progression to active myeloma.…
News Article
Myeloma Support Group Leader Voices at ASH
By Robin Tuohy, IMF Vice President, Support Groups
Every year in December, the Annual Meeting & Exposition of the American Society of Hematology (ASH) serves as a premier opportunity for researchers and clinicians to…
Page
What Is Mezigdomide?Mezigdomide is a CELMoD agent that is being studied in many clinical trials with different drug combinations and in different myeloma patient populations.What Are CELMoDs?Cereblon (CRBN) E3 ligase modulators (CELMoDs) are a new drug class in myeloma. The emergence of…
Page
What Is Iberdomide?Iberdomide is a CELMoD agent that is being studied in many clinical trials with different drug combinations and in different myeloma patient populations.What Are CELMoDs?Cereblon (CRBN) E3 ligase modulators (CELMoDs) are a new drug class in myeloma. The emergence of CELMoDs…
IMF Person
With 17 years of expertise in continuing medical education, Joi joined the IMF in December 2023. Her extensive background includes invaluable contributions to project management teams, delivering excellence in outcomes and insights. Joi is driven by a profound commitment to project success,…
IMF Person
Sandy is a seasoned grants manager with extensive experience in project management and leading effective and compliant solutions for sponsorship funding processes as well as experience in public opinion research. Prior to joining the IMF, Sandy worked at Karyopharm Therapeutics, a…
News Article
Positive Results from the DREAMM-8 Phase III Trial of Blenrep in Myeloma Treatment
In a March 7, 2024 press release from GSK, the following was reported: "Positive headline results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in…
Videos
Mass Spectrometry for the Measurement of Multiple Myeloma Protein Levels
Myeloma expert Dr. Brian G.M. Durie explores the significance of mass spectrometry, a sensitive monitoring technique, in measuring myeloma protein levels for diagnosis and monitoring.
Dr. Durie…
News Article
Uniting Voices, Connecting Lives: Empowering Myeloma Communities Together
90 leaders of 74 myeloma support groups gathered for the 24th annual IMF Support Group Leaders Summit
By Robin Tuohy, IMF Vice President, Support Groups
Over the span of 24 years…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the February 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
Four Drug Combination for First Time Myeloma Treatment
Myeloma expert Dr. Brian G.M. Durie discusses the feasibility of using a four-drug combination as the firstline therapy for multiple myeloma.
Dr. Durie discusses the use of a four-drug combination as front-line therapy,…
News Article
International Myeloma Foundation (IMF) Launches #MyelomaActionMonth for 2024 March Myeloma Action Month
Partnering with GMAN, Global Campaign Focuses on Raising Awareness and Taking Action for Myeloma to Bring Hope to Patients and Care Partners
STUDIO CITY,…
News Article
According to a press release from Legend Biotech, "the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expansion of the CARVYKTI® label to include adult patients with relapsed and refractory multiple myeloma, who have received at least…
Videos
Real World Outcomes with Ide-Cel CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Dr. Surbhi Sidana discusses the largest real-world study that looks at the Ide-Cel CAR T-cell therapy in the relapsed/refractory multiple myeloma population.
Abstract Title:…
News Article
According to a press release from Regeneron, the U.S. FDA "has accepted for Priority Review the Biologics License Application (BLA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies. The target…
News Article
According to a February 20, 2023 press release from Johnson & Johnson, the U.S. FDA has "approved the supplemental Biologics License Application (sBLA) for TECVAYLI® (teclistamab-cqyv) for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory…
Videos
Early Screening for Myeloma: Impact on the Face of Myeloma
Myeloma expert Dr. Brian G.M. Durie explores how the face of myeloma is changing with the help of early screening and detection of monoclonal spikes in individuals at risk for myeloma.
Dr. Durie discusses the…
Videos
Promising Early Safety Profile of P-BCMA-ALLO1 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma Patients
Dr. Dholaria Bhagirathbhai presents the early safety results of P-BCMA-ALLO1 in relapsed/refractory multiple myeloma patients with measurable disease who have received a…
Videos
Determination Phase 3 Trial: RVd Alone Versus Rvd Plus Autologous Stem Cell Transplantation in Newly Diagnosed African American Patients
Dr. Paul G. Richardson reports on the use of RvD alone versus RvD alongside an autologous stem cell transplantation (ASCT) in the treatment of newly diagnosed…
Videos
Mezigdomide (MEZI) Combination Therapy for Relapsed/Refractory Multiple Myeloma – Insights from CC-92480-MM-002 Trial
Dr. Paul G. Richardson reports on the use of various mezigdomide combinations in the treatment of relapsed/refractory multiple myeloma.
Abstract Title…
News Article
According to a press release from Pfizer, Health Canada has granted a Notice of Compliance with conditions (NOC/c) to ELREXFIOTM (elranatamab solution for injection), marking its approval for use in the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM).…
News Article
STUDIO CITY, CA, February 13, 2024 — The International Myeloma Foundation (IMF) is excited to announce the launch of the Iceland Cycling Expedition (ICE)—a 3-day, 2-night fundraiser biking tour set to take place from August 29 - September 4, 2024, in Reykjavik and around Iceland to…
Page
Asian Myeloma Network Annual Summit 2025
This meeting announcement is for the IMF Asian Myeloma Network Health Care Practitioner Membership. Questions can be directed to IMF AMN Executive Staff, Dan Navid or Lisa Paik ([email protected], [email protected])
Videos
Ice-T Sets The Record Straight On Multiple Myeloma, "It's Not Melanoma."
Let's talk about the most common blood cancer in African Americans.
It hits hard, but together, we can educate, fight, and raise awareness. Know the signs, symptoms. Talk to your doctor.